Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions

Prostate Cancer

Interventions

DRUG

Androgen deprivation therapy (ADT)

"* Goserelin: AstraZeneca, 10.8mg injection~* ADT will be applied for 12 months in total~* ADT must be given concurrently and adjuvant"

Trial Locations (1)

RECRUITING

German Oncology Center, Limassol